ArticleBMC cancer2021
Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M.
Yurong Wang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
18 papers cite it
this papercites it